European Federation of Pharmaceutical Industries and Associations

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article includes a list of general references, but it lacks sufficient corresponding inline citations. Please help to improve this article by introducing more precise citations. (May 2014) (Learn how and when to remove this message) This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (August 2010) (Learn how and when to remove this message) (Learn how and when to remove this message)

The European Federation of Pharmaceutical Industries and Associations (EFPIA) is a Brussels-based trade association and lobbying organisation, founded in 1978 and representing the pharmaceutical industry operating in Europe. Through its membership of 36 national associations and 39 leading pharmaceutical companies,^[1] the EFPIA represents 1,900 European companies.^[2]

Key Information

European Federation of Pharmaceutical Industries and Associations
Formation	1978
Founded at	Brussels, Belgium
Purpose	Trade association
Location	Brussels, Belgium
Region served	Europe
Membership	37 national associations, 55 corporate members
Key people	Nathalie Moll (General Director) Lars Fruergaard Jørgensen (Chairman of the Board)
Staff	60 (2023)
Website	www.efpia.eu
Show more

EFPIA priorities include speeding up regulatory approval and reimbursement processes for new medicines, creating a strong science base in Europe, joining forces with key stakeholders on political issues concerning health and addressing safety concerns. EFPIA also includes specialised groups like Vaccines Europe^[3] who produce approximately 80% of vaccines used worldwide and European Biopharmaceutical Enterprises harness biotechnology to develop approximately one-fifth of new medicines.

The Innovative Medicines Initiative (IMI) is a public-private partnership designed by the European Commission and EFPIA. It is a pan-European collaboration that brings together large biopharmaceutical companies, small- and medium-sized enterprises (SMEs), patient organisations, academia, hospitals and public authorities. The initiative aims to accelerate the discovery and development of better medicines by removing bottlenecks in the drug development process. It focuses on creating better methods and tools to improve and enhance the drug development process, rather than developing specific, new medicines.

From 1991 to 1998 Emer Cooke worked for the EFPIA.^[4] She became executive director of the European Medicines Agency (EMA), an agency of the European Union (EU) in charge of the evaluation and supervision of medicinal products, in November 2020.^[5]

In a session of the Austrian Parliament member of parliament Gerald Hauser on 1 April 2021 publicly criticised a potential conflict of interest, by her allowing the controversial Oxford–AstraZeneca COVID-19 vaccine to be approved, while having worked for the very same industry in the past as a lobbyist of the EFPIA.^[6][7]

• European and Developing Countries Clinical Trials Partnership (EDCTP)
• EuropaBio
• European Federation of Biotechnology (EFB)
• International Federation of Pharmaceutical Manufacturers Associations (IFPMA)
• Pharmaceutical Research and Manufacturers of America (PhRMA)

• Official website of the European Federation of Pharmaceutical Industries and Associations – (EFPIA)
• Innovative Medicines Initiative (IMI)
• Vaccines Europe (VE)
• European Biopharmaceutical Enterprises (EBE) (archived)